Soleno Therapeutics (NASDAQ:SLNO) PT Raised to $74.00 at Stifel Nicolaus

Soleno Therapeutics (NASDAQ:SLNO) had its price objective upped by Stifel Nicolaus from $59.00 to $74.00 in a research report sent to investors on Tuesday, Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Several other research firms have also issued reports on SLNO. Oppenheimer increased their price target on shares of Soleno Therapeutics from $59.00 to $65.00 and gave the stock an outperform rating in a research report on Monday, August 12th. Cantor Fitzgerald reissued an overweight rating and issued a $67.00 target price on shares of Soleno Therapeutics in a report on Friday, September 20th. Finally, HC Wainwright assumed coverage on Soleno Therapeutics in a research note on Tuesday, September 3rd. They issued a buy rating and a $70.00 price target on the stock. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of Buy and an average target price of $68.71.

Soleno Therapeutics Stock Up 1.4 %

Soleno Therapeutics stock opened at $49.63 on Tuesday. The business has a 50 day moving average price of $48.87 and a two-hundred day moving average price of $45.08. Soleno Therapeutics has a 12 month low of $21.30 and a 12 month high of $55.56. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -18.52 and a beta of -1.45.

Soleno Therapeutics (NASDAQ:SLNO) last issued its earnings results on Wednesday, August 7th. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.06. On average, analysts expect that Soleno Therapeutics will post -2.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Soleno Therapeutics

In other Soleno Therapeutics news, insider Kristen Yen sold 3,108 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $49.43, for a total value of $153,628.44. Following the transaction, the insider now directly owns 81,465 shares in the company, valued at $4,026,814.95. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Soleno Therapeutics news, CFO James H. Mackaness sold 8,077 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $49.43, for a total value of $399,246.11. Following the transaction, the chief financial officer now directly owns 119,172 shares in the company, valued at $5,890,671.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kristen Yen sold 3,108 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $49.43, for a total transaction of $153,628.44. Following the transaction, the insider now owns 81,465 shares in the company, valued at $4,026,814.95. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 771,441 shares of company stock worth $37,178,033 over the last ninety days. Corporate insiders own 12.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Amalgamated Bank bought a new position in Soleno Therapeutics in the 2nd quarter valued at $31,000. Victory Capital Management Inc. boosted its holdings in Soleno Therapeutics by 26.3% in the second quarter. Victory Capital Management Inc. now owns 10,727 shares of the company’s stock valued at $438,000 after acquiring an additional 2,236 shares during the last quarter. Cannon Global Investment Management LLC bought a new position in Soleno Therapeutics in the first quarter valued at about $505,000. Sei Investments Co. increased its position in Soleno Therapeutics by 22.0% in the first quarter. Sei Investments Co. now owns 12,577 shares of the company’s stock worth $538,000 after purchasing an additional 2,264 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in Soleno Therapeutics in the second quarter worth about $569,000. Institutional investors own 97.42% of the company’s stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.